secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0001193125-24-222189
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic reports positive Phase 1a data for TX45; Phase 2 doses selected, Phase 1b dose escalated
--------------------------------------------------------------------------------

- Phase 1a: TX45 well-tolerated, no immunogenicity, robust PK/PD; Phase 2 doses set at 300 mg SC monthly or every other week.
- Phase 1b hemodynamic trial in PH-HFpEF escalated to 3 mg/kg IV; topline results expected Q2 2025.
- Phase 2 APEX trial screening initiated; topline results anticipated in 2026.
- Full Phase 1a results to be presented at AHA Scientific Sessions November 2024.
- Over 600,000 patients estimated with Group 2 PH-HFpEF; no approved treatments currently.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312524222189/0001193125-24-222189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312524222189/d667336d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-222189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer